Video

Frederick Munschauer: Treatment of Progressive Multiple Sclerosis Remains a Daunting Task

Author(s):

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help them.

There has been work done in this area of research and medications, including Ocrelizumab working through the approval process but Frederick Munschauer, MD, from EMD Serono said the process of developing more treatment options is still ongoing. Munschauer discussed the topic during an interview with MD Magazine during the annual meeting of the Consortium of Multiple Sclerosis Centers in National Harbor Maryland.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.